Overview

Anakinra as a Rescue Treatment for Allergic Inflammation

Status:
Suspended
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
Participants with mild asthma who are sensitized to either house dust mite or cat hair allergen will undergo nasal instillation of the allergen to elicit nasal allergy symptoms. The participants will be treated in a cross-over fashion with either placebo (saline) or anakinra to determine if anakinra will reduce nasal airway eosinophil recruitment, eosinophil activation, release of inflammatory mediators, mucins, and gene expression changes in epithelial cells.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Interleukin 1 Receptor Antagonist Protein